11 March 2020

HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies

Further expansion of HORAMA gene therapy portfolio to treat Inherited Retinal Dystrophies to lead to second clinical program by 2023 Paris (France) and Leiden (Netherlands), March […]
11 March 2020

HORAMA Strengthens Its Management Team With the Appointment of Rodolphe Clerval as Chief Business Officer (CBO)

Paris, March 11, 2020 – HORAMA, a clinical stage gene therapy company in ophthalmology, today announced that Rodolphe Clerval has been appointed as Chief Business Officer […]
18 September 2018

HORAMA completes its 22.5 million euros “Series B” financing round

Paris (France), September 18th, 2018 – Horama (www.horama.fr), a French biotech company based in Paris and Nantes, which specialises in gene therapy for the treatment of […]
11 July 2018

HORAMA announces initiation of a Phase I/II Clinical Study for HORA-PDE6B, in Retinitis Pigmentosa (RP)

Paris, July 11, 2018 – Horama, a French biotech company based in Paris and Nantes, which specialises in gene therapy for the treatment of rare, inherited […]
16 May 2018

HORAMA Appoints Dr Russell Greig as New Chairman of the Board

Paris, May 15, 2018 – Horama, a French biotech company based in Paris and Nantes, which specialises in gene therapy for the treatment of rare, inherited […]
24 November 2017

Horama raises €19 million in a Series B financing round

Horama raises 19 million euros from new investors (Kurma Partners, Fund+, Pontifax and Idinvest) and existing investors (Omnes Capital, GO Capital and Sham Innovation Santé/Turenne) to […]
11 October 2017

Horama Granted Authorization to Conduct Phase I/II Clinical Study for HORA-PDE6B, in Retinitis Pigmentosa (RP)

Paris , October 11, 2017 – Horama, a French biotech co mpany based in Paris and Nantes, which specialises in gene therapy for the treatment of […]
10 July 2017

Horama Granted Orphan Drug Designation (ODD) In U.S. For Drug Candidate HORA-RLBP1

Paris, France, July 10, 2017 – Horama (www.horama.fr), a French biotech company based in Paris and specialized in gene therapy for the treatment of rare inherited […]
29 June 2017

Horama welcomes three new experts to bolster its team

• Jean – Yves Deslandes – Chief Medical Officer • Nicolas Delaunay – Head of CMC Regulatory Affairs • Jérôme Vailland – Chief Financial Officer   […]
11 July 2016

Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital

Proceeds from this fundraising will be used to: Bring HORA-PDE6B into the clinic, Accelerate HORA-RLPB1 development, Reinforce Horama’s team. Paris, France, July 8, 2016 – Horama, one […]